<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6059">
  <stage>Registered</stage>
  <submitdate>25/01/2016</submitdate>
  <approvaldate>25/01/2016</approvaldate>
  <nctid>NCT02684006</nctid>
  <trial_identification>
    <studytitle>A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)</studytitle>
    <scientifictitle>A Phase 3, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) In Combination With Axitinib (Inlyta(Registered)) Versus Sunitinib (Sutent(Registered)) Monotherapy In The First-line Treatment Of Patients With Advanced Renal Cell Carcinoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-002429-20</secondaryid>
    <secondaryid>B9991003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Renal Cell Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Avelumab (MSB0010718C)
Treatment: drugs - Axitinib (AG-013736)
Treatment: drugs - Sunitinib

Experimental: Avelumab in combination with axitinib - Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.

Active Comparator: Sunitinib - Sunitinib given at 50 mg PO QD on schedule 4/2


Treatment: drugs: Avelumab (MSB0010718C)
IV treatment Avelumab administered at 10 mg/kg IV every two weeks

Treatment: drugs: Axitinib (AG-013736)
Oral treatment Axitinib given 5 mg PO BID

Treatment: drugs: Sunitinib
Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) in PD-L1 positive patients - Progression Free Survival (PFS) is the time from randomization to date of first documentation of objective progression of disease assessed by BICR (by RECIST version 1.1) or death due to any cause.</outcome>
      <timepoint>From randomization up to 30 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Overall Survival in PD-L1 positive patients - OS is the time from date of randomization to date of death due to any cause.</outcome>
      <timepoint>Every 3 months up to 5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) in unselected patients - OS is the time from date of randomization to date of death due to any cause.</outcome>
      <timepoint>Every 3 months up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with Objective Response (OR) - Number of participants with objective response (ie, confirmed complete or partial response according to RECIST Version 1.1 recorded from randomization until disease progression assessed by BICR or death due to any cause)</outcome>
      <timepoint>Every 6 weeks up to 18 months from patient enrollment in the study, then every 12 weeks up to 30 months from randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Control (DC) - DC is defined as complete response (CR), partial response (PR), or stable disease (SD) according to the RECIST v.1.1 recorded from randomization until disease progression assessed by BICR or death due to any cause.</outcome>
      <timepoint>Every 6 weeks up to 18 months from patient enrollment in the study, then every 12 weeks up to 30 months from randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Tumor Response (TTR) - TRR is the time from randomization to first documentation of objective tumor response (CR or PR).</outcome>
      <timepoint>Every 6 weeks up to 18 months from patient enrollment in the study, then every 12 weeks up to 30 months from randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DR) - DR is the time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression assessed by BICR or death due to any cause</outcome>
      <timepoint>Every 6 weeks up to 18 months from patient enrollment in the study, then every 12 weeks up to 30 months from randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) by Investigator assessment - Progression Free Survival (PFS) is the time from randomization to date of first documentation of objective progression of disease assessed by the Investigator (by RECIST version 1.1) or death due to any cause.</outcome>
      <timepoint>Every 6 weeks up to 18 months from patient enrollment in the study, then every 12 weeks up to 30 months from randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough plasma concentration (Ctrough) of avelumab - Ctrough is defined as the concentration at the end of avelumab dosage interval</outcome>
      <timepoint>Pre-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough plasma concentration (Ctrough) of axitinib - Ctrough is defined as the concentration at the end of axitinib dosage interval</outcome>
      <timepoint>Pre-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum plasma concentration (Cmax) of axitinib - Cmax defined as the maximum plasma concentration of axitinib</outcome>
      <timepoint>2 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-Drug Antibody (ADA) levels of avelumab/Neutralizing antibodies titers for MSB0010718C - Immunogenicity assessment of avelumab</outcome>
      <timepoint>Pre-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor tissue biomarker status - Biomarker status defined as positive or negative based on a pre-specified scoring algorithm involving, for example, PD-L1 expression and/or quantitation of tumor infiltrating CD8+T lymphocytes as assessed by IHC</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) in biomarker-positive and biomarker-negative subgroups - OS in biomarker-negative and biomarker-positive subgroups.</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in FACT-Kidney Symptom Index (FKSI)-19 - The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains- Disease Related Symptoms (physical and emotional), Treatment related side effects and Functional and Well-Being . A negative change from Baseline represents a worsening of condition.</outcome>
      <timepoint>Every 6 weeks up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in European Quality of Life Questionnaire (EQ-5D) - Health State Profile - EQ-5D Health State Profile: participant rated questionnaire to assess health-related quality of life in terms of a single index value.</outcome>
      <timepoint>Every 6 weeks up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) in biomarker-positive and biomarker-negative subgroups - PFS as measure of clinical outcome in biomarker-negative and biomarker-positive subgroups.</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response (OR) in biomarker-positive and biomarker-negative subgroups - OR in biomarker-negative and biomarker-positive subgroups</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Control (DC) in biomarker-positive and biomarker-negative subgroups - DC in biomarker-negative and biomarker-positive subgroups</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time To Response (TTR) in biomarker-positive and biomarker-negative subgroups - TTR in biomarker-negative and biomarker-positive subgroups.</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DR) in biomarker-positive and biomarker-negative subgroups - DR in biomarker-negative and biomarker-positive subgroups.</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in European Quality of Life Questionnaire (EQ-5D) - Visual Analogic Scale - EQ-5D Visual Analogic Scale:patients rated their overall health status from 0 (worst imaginable heath state) to 100 (best imaginable heath state).</outcome>
      <timepoint>Every 6 weeks up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to treatment discontinuation/failure due to toxicity (TTF) - TTF is defined as the time from Cycle 1 Day 1 to the date of the first documentation of discontinuation due to an adverse event or death due to study treatment toxicity</outcome>
      <timepoint>From Cycle 1 Day 1, every 6 weeks up to the End of Treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment discontinuation/failure due to toxicity - Treatment discontinuation is the percentage of patients who discontinue the treatment due to an adverse event or death due to study treatment toxicity</outcome>
      <timepoint>From Cycle 1 Day 1, every 6 weeks up to the End of Treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PFS on next-line therapy (PFS2) - PFS2 is defined as the time from randomization to discontinuation of next line treatment, second objective disease progression, or death from any cause, whichever occurs first.</outcome>
      <timepoint>From randomization up to 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) in unselected patients - Progression Free Survival (PFS) is the time from randomization to date of first documentation of objective progression of disease assessed by BICR (by RECIST version 1.1) or death due to any cause.</outcome>
      <timepoint>From randomization up to 30 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically or cytologically confirmed advanced or metastatic RCC with clear cell
             component

          -  Availability of a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block from a
             de novo tumor biopsy during screening (biopsied tumor lesion should not be a RECIST
             target lesion). Alternatively, a recently obtained archival FFPE tumor tissue block
             (not cut slides) from a primary or metastatic tumor resection or biopsy can be
             provided if the following criteria are met: 1) the biopsy or resection was performed
             within 1 year of randomization AND 2) the patient has not received any intervening
             systemic anti-cancer treatment from the time the tissue was obtained and randomization
             onto the current study. If an FFPE tissue block cannot be provided as per documented
             regulations then, 15 unstained slides (10 minimum) will be acceptable

          -  Availability of an archival FFPE tumor tissue from primary tumor resection specimen
             (if not provided per above). If an FFPE tissue block cannot be providedas per
             documented regulations 15 unstained slides (10 minimum) will be acceptable

          -  At least one measureable lesion as defined by RECIST version 1.1 that has not been
             previously irradiated

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Adequate bone marrow function, renal and liver functions</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior systemic therapy directed at advanced or metastatic RCC

          -  Prior adjuvant or neoadjuvant therapy for RCC if disease progression or relapse has
             occurred during or within 12 months after the last dose of treatment.

          -  Prior immunotherapy with IL-2, IFN-a, or anti PD 1, anti PD L1, anti PD L2, anti
             CD137, or anti cytotoxic T lymphocyte associated antigen 4 (CTLA 4) antibody
             (including ipilimumab), or any other antibody or drug specifically targeting T cell co
             stimulation or immune checkpoint pathways

          -  Prior therapy with axitinib and/or sunitinib as well as any prior therapies with other
             VEGF pathway inhibitors

          -  Newly dignosed or active brain metastasis

          -  Known severe hypersensitivity reactions to monoclonal antibodies (Grade =3), any
             history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partially
             controlled asthma Global Initiative for Asthma 2011)

          -  Any of the following in the previous 12 months: myocardial infarction, severe/unstable
             angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure,
             LVEF less than LLN, clinically significant pericardial effusion, cerebrovascular
             accident, transient ischemic attack

          -  Any of the following in the previous 6 months: deep vein thrombosis or symptomatic
             pulmonary embolism

          -  Vaccination within 4 weeks of the first dose of avelumab and while on trial is
             prohibited except for administration of inactivated vaccines (for example, inactivated
             influenza vaccines)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>23/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>830</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/04/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Macquarie University Hospital Pharmacy - Macquarie University</hospital>
    <hospital>Macquarie University - Macquarie University</hospital>
    <hospital>Nuclear Medicine Department - Randwick</hospital>
    <hospital>Pharmacy Department, Clinical Trials - Randwick</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Spectrum Medical Imaging - Randwick</hospital>
    <hospital>Division of Cancer Services - Woolloongabba</hospital>
    <hospital>Main Pharmacy - Woolloongabba</hospital>
    <hospital>Metro South Health Queensland - Woolloongabba</hospital>
    <hospital>Lake Imaging - Ballarat</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Eastern Health - Box Hill</hospital>
    <hospital>Monash Health Translational Precinct - Clayton</hospital>
    <hospital>Moorabbin Radiology - East Bentleigh</hospital>
    <hospital>Monash Cancer Centre - East Bentleigh</hospital>
    <hospital>Ballarat Day Procedure Centre - Wendouree</hospital>
    <hospital>Ballarat Oncology &amp; Haematology Services - Wendouree</hospital>
    <hospital>Nova Pharmacy - Wendouree</hospital>
    <hospital>Slade Health - West Melbourne</hospital>
    <hospital>SKG Radiology - Murdoch</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <hospital>St John of God Murdoch Hospital - Murdoch</hospital>
    <hospital>EPIC Pharmacy Murdoch - Perth</hospital>
    <postcode>2109 - Macquarie University</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3350 - Ballarat</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3156 - East Bentleigh</postcode>
    <postcode>3165 - East Bentleigh</postcode>
    <postcode>3355 - Wendouree</postcode>
    <postcode>3003 - West Melbourne</postcode>
    <postcode>6050 - Murdoch</postcode>
    <postcode>6150 - Murdoch</postcode>
    <postcode>6150 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Kortrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liège</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herlev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense C</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>CAEN cedex 05</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen, Cedex 05</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Mans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon cedex 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>LYON cedex 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Herblain Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-wuerttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>North Rhine-westphalia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Thuringia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kaposvár</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat - Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Yaakov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>(pn)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aomori</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaidô</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Iwate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shizuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Akita</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Niigata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokushima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Yamagata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daejeon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Nuevo Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Oaxaca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Noord-holland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zuid-holland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Haarlem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Hoofddorp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Veldhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Bay of Plenty</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Manawatu-wanganui</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Palmerston North</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj-Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Craiova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kaluga Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kursk Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Poselok Pesochniy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhniy Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yaroslavl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Gothenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridgeshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey, London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab
      in combination with axitinib and of sunitinib monotherapy, administered as first-line
      treatment, in patients with advanced renal cell carcinoma</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02684006</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address />
      <phone>1-800-718-1021</phone>
      <fax />
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>